| P50 | author | Stephen J. Russell | Q53843820 |
| | Kah-Whye Peng | Q88612764 |
| | Nathan J Jenks | Q117250253 |
| | Lukkana Suksanpaisan | Q117250255 |
| | Mulu Z. Tesfay | Q117250274 |
| P2093 | author name string | Rong Xu | |
| | Rianna Vandergaast | |
| | Rosa Maria Diaz | |
| | John H Eldridge | |
| | David K Clarke | |
| | Ayuko Ota-Setlik | |
| | Stefan Hamm | |
| | Rebecca Nowak | |
| | Amara Luckay | |
| | Michael B Steele | |
| | Carolyn Bomidi | |
| | Hinna Akhtar | |
| P2860 | cites work | Perspectives for therapeutic HPV vaccine development | Q28069272 |
| | Safety Studies in Tumor and Non-Tumor-Bearing Mice in Support of Clinical Trials Using Oncolytic VSV-IFNβ-NIS. | Q33434692 |
| | Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal. | Q33608156 |
| | Evidence-Based Treatment Options in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck | Q33650470 |
| | Vesicular stomatitis virus as a novel cancer vaccine vector to prime antitumor immunity amenable to rapid boosting with adenovirus | Q33713083 |
| | Pembrolizumab in cervical cancer: latest evidence and clinical usefulness | Q33757149 |
| | Safety studies on intrahepatic or intratumoral injection of oncolytic vesicular stomatitis virus expressing interferon-beta in rodents and nonhuman primates | Q33832168 |
| | Human papillomavirus type 16 E6-induced degradation of E6TP1 correlates with its ability to immortalize human mammary epithelial cells | Q33840139 |
| | Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy | Q33933665 |
| | Using virally expressed melanoma cDNA libraries to identify tumor-associated antigens that cure melanoma | Q34198856 |
| | Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group | Q34313864 |
| | Recombinant vesicular stomatitis viruses from DNA. | Q34337129 |
| | Biological activities and molecular targets of the human papillomavirus E7 oncoprotein | Q34468787 |
| | Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial | Q34488529 |
| | Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes for adoptive immunotherapy of HPV-associated malignancies. | Q34501316 |
| | Oral human papillomavirus (HPV) infection in HPV-positive patients with oropharyngeal cancer and their partners | Q34682692 |
| | Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers | Q34760882 |
| | Ability of the matrix protein of vesicular stomatitis virus to suppress beta interferon gene expression is genetically correlated with the inhibition of host RNA and protein synthesis | Q34857223 |
| | Comparative Immunogenicity in Rhesus Monkeys of DNA Plasmid, Recombinant Vaccinia Virus, and Replication-Defective Adenovirus Vectors Expressing a Human Immunodeficiency Virus Type 1 gag Gene | Q34996554 |
| | Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity | Q35182301 |
| | Activating systemic T-cell immunity against self tumor antigens to support oncolytic virotherapy with vesicular stomatitis virus | Q35575688 |
| | Transcription of human papillomavirus type 16 early genes in a cervical cancer and a cancer-derived cell line and identification of the E7 protein | Q35614019 |
| | Synergistic attenuation of vesicular stomatitis virus by combination of specific G gene truncations and N gene translocations. | Q35635393 |
| | Vesicular stomatitis virus: re-inventing the bullet | Q35761892 |
| | Oncolytic Vesicular Stomatitis Virus as a Viro-Immunotherapy: Defeating Cancer with a "Hammer" and "Anvil". | Q54378300 |
| | Strong association between infection with human papillomavirus and oral and oropharyngeal squamous cell carcinoma: a population-based case-control study in southern Sweden. | Q54630232 |
| | Oncolytic immunotherapy: an emerging new modality for the treatment of cancer | Q89409422 |
| | Mutational analysis of human papillomavirus type 16 E6 demonstrates that p53 degradation is necessary for immortalization of mammary epithelial cells | Q35854157 |
| | First-in-Human Evaluation of the Safety and Immunogenicity of a Recombinant Vesicular Stomatitis Virus Human Immunodeficiency Virus-1 gag Vaccine (HVTN 090). | Q35858437 |
| | Heterologous prime/boost immunization of rhesus monkeys by using diverse poxvirus vectors | Q35947690 |
| | Vesicular stomatitis virus as an oncolytic vector | Q36020593 |
| | Single-dose, therapeutic vaccination of mice with vesicular stomatitis virus expressing human papillomavirus type 16 E7 protein | Q36672543 |
| | Immunovirotherapy with vesicular stomatitis virus and PD-L1 blockade enhances therapeutic outcome in murine acute myeloid leukemia | Q36700481 |
| | Intratumoral injection of therapeutic HPV vaccinia vaccine following cisplatin enhances HPV-specific antitumor effects | Q36949240 |
| | Cellular transformation by human papillomaviruses: lessons learned by comparing high- and low-risk viruses | Q36989890 |
| | Type I interferon as a stimulus for cross-priming | Q37027815 |
| | Oncolytic vesicular stomatitis virus as a treatment for neuroendocrine tumors | Q37325067 |
| | In vivo biodistribution of a highly attenuated recombinant vesicular stomatitis virus expressing HIV-1 Gag following intramuscular, intranasal, or intravenous inoculation | Q37354600 |
| | Molecular determinants of susceptibility to oncolytic vesicular stomatitis virus in pancreatic adenocarcinoma | Q37646792 |
| | VSV-GP: a potent viral vaccine vector that boosts the immune response upon repeated applications. | Q37714030 |
| | Clinical development of a recombinant Ebola vaccine in the midst of an unprecedented epidemic | Q38375013 |
| | Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study | Q38405569 |
| | Robust Oncolytic Virotherapy Induces Tumor Lysis Syndrome and Associated Toxicities in the MPC-11 Plasmacytoma Model | Q38734741 |
| | Worldwide burden of cancer attributable to HPV by site, country and HPV type. | Q38859779 |
| | Oncolytic Viruses in Cancer Treatment: A Review. | Q38904006 |
| | Oncolytic Virotherapy: A Contest between Apples and Oranges | Q39230055 |
| | Viral Infection of Tumors Overcomes Resistance to PD-1-immunotherapy by Broadening Neoantigenome-directed T-cell Responses. | Q39791206 |
| | The minimal conserved transcription stop-start signal promotes stable expression of a foreign gene in vesicular stomatitis virus. | Q39874034 |
| | Customized Viral Immunotherapy for HPV-Associated Cancer | Q40040094 |
| | Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy. | Q40050674 |
| | Sharpening the Edge for Precision Cancer Immunotherapy: Targeting Tumor Antigens through Oncolytic Vaccines | Q40104793 |
| | Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer | Q40242985 |
| | Requirement for a non-specific glycoprotein cytoplasmic domain sequence to drive efficient budding of vesicular stomatitis virus | Q41051042 |
| | Systemic combination virotherapy for melanoma with tumor antigen-expressing vesicular stomatitis virus and adoptive T-cell transfer | Q41875584 |
| | Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. | Q42810754 |
| | Endogenous and pharmacologic targeting of the STING pathway in cancer immunotherapy | Q43146562 |
| | Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus | Q43599369 |
| | Comparative oncology evaluation of intravenous recombinant oncolytic Vesicular Stomatitis Virus therapy in spontaneous canine cancer | Q45324545 |
| | Antitumor efficacy of Venezuelan equine encephalitis virus replicon particles encoding mutated HPV16 E6 and E7 genes | Q45705136 |
| | Localized attenuation and discontinuous synthesis during vesicular stomatitis virus transcription | Q45802541 |
| | Review: Oncolytic virotherapy, updates and future directions | Q47160989 |
| | Antitumor Benefits of Antiviral Immunity: An Underappreciated Aspect of Oncolytic Virotherapies | Q47560736 |
| | Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity | Q47644096 |
| | Human papillomavirus type 16 DNA sequence | Q48376786 |
| P921 | main subject | oncolytic virus | Q1560099 |
| P304 | page(s) | 1-13 | |
| P577 | publication date | 2018-07-05 | |
| P1433 | published in | Molecular therapy oncolytics | Q27726823 |
| P1476 | title | Preclinical Development of Oncolytic Immunovirotherapy for Treatment of HPVPOS Cancers. | |
| P478 | volume | 10 | |